Prostate Cancer Oral SACT Pathway Service Optimization Report

This document is a report detailing the outputs of a collaborative working project between Astellas Pharma Ltd and University Hospitals Birmingham NHS Foundation Trust, focusing on the optimization of the Prostate Cancer Oral Systemic Anti-Cancer Therapy (SACT) pathway. The objective is to publish findings from the service review of the Prostate Cancer Oral SACT Novel Hormone Therapy pathway, which aims to redesign and enhance the efficiency of the service. The report outlines the identification of bottlenecks and inefficiencies within the current pathway, including staffing challenges, inconsistent follow-up clinic approaches, and limitations in allied health professional support. Additionally, it presents solutions to improve clinic flow, such as aligning patients to correct follow-up intervals and developing allied health professional-led clinics across all sites. The report also highlights patient satisfaction levels and the quality of treatment information provided, emphasizing the importance of addressing identified issues to enhance service delivery.